{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-051209","form_type":"8-K","ticker":"FBLG","cik":"0001958777","company_name":"FibroBiologics, Inc.","filed_at":"2024-12-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.440229+00:00","generated_at":"2026-05-28T23:52:51.808242+00:00","sec_items":["1.01","2.03","3.02","7.01","9.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"FibroBiologics secures up to $25M standby equity facility with Yorkville; first $5M funded","bullets":["Yorkville advanced $5M initial tranche of $15M pre-paid convertible notes; two additional $5M tranches subject to conditions.","Conversion price lower of $2.41/share or 94% of 5-day VWAP; 0% interest (18% upon default), matures Dec 2025.","Additional $10M common stock purchase commitment available under SEPA over two years, subject to Yorkville's consent.","CEO states proceeds will fund first-in-human diabetic foot ulcer trial and psoriasis IND-enabling studies.","Shareholder approval required for issuances exceeding 19.99% of outstanding shares (Exchange Cap)."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-051209","json":"https://secwatch.observer/filing/0001493152-24-051209.json","markdown":"https://secwatch.observer/filing/0001493152-24-051209.md","text":"https://secwatch.observer/filing/0001493152-24-051209.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1958777/000149315224051209/0001493152-24-051209-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1958777/000149315224051209/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T23:52:51.808242+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}